Stent News and Research RSS Feed - Stent News and Research

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.
Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Study compares latest drug-coated stents with traditional bypass surgery

Study compares latest drug-coated stents with traditional bypass surgery

Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery. [More]
Endovascular aneurysm repair procedure can extend lives even in high-risk patients: Study

Endovascular aneurysm repair procedure can extend lives even in high-risk patients: Study

Minimally invasive surgery can prevent a fatal rupture of an abdominal aortic aneurysm. [More]
Cook Medical receives CE Mark for new thumbwheel deployment system for Zilver PTX drug-eluting peripheral stent

Cook Medical receives CE Mark for new thumbwheel deployment system for Zilver PTX drug-eluting peripheral stent

CE Mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver PTX drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for the world’s first and only approved drug-eluting stent for the superficial femoral artery (SFA). [More]
VENITI closes $17 million in equity and debt financing

VENITI closes $17 million in equity and debt financing

VENITI, Inc., a St. Louis, MO-based medical device company is pleased to announce that it has closed on an equity and debt financing totaling over $17 million. The equity portion, its Series C, was led by previous investors, Baird Capital and Tekla Healthcare and Tekla Life Science Investors, with strong internal participation. [More]
Duke researchers find major shift in treatments for peripheral artery disease

Duke researchers find major shift in treatments for peripheral artery disease

Federal efforts to curb Medicare costs for unclogging blood vessels in the limbs slowed the growing use of the treatments, but also coincided with a marked increase in doctors using a more expensive approach, according to an analysis by Duke Medicine researchers. [More]
Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin (LMWH), although both groups had similar rates of subsequent heart attack or stroke, according to a study in the February 17 issue of JAMA. [More]

Boston Scientific, Johnson & Johnson settle breach of merger agreement lawsuit

Boston Scientific Corporation today announced the settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson against Guidant Corporation, stemming from Boston Scientific's acquisition of Guidant. [More]
Landmark stroke studies presented at ISC, published in NEJM suggest new treatment protocol on the horizon

Landmark stroke studies presented at ISC, published in NEJM suggest new treatment protocol on the horizon

Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire™ Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke. [More]
Biosensors' total revenue decreases 6.06% to of $77.5 million in Q3 FY15

Biosensors' total revenue decreases 6.06% to of $77.5 million in Q3 FY15

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, today announced financial results for the third quarter of its Fiscal Year 2015 ("Q3 FY15") and nine months ended 31 December 2014 ("FY15 nine-month period"). [More]
Endovascular treatment can improve patient outcomes after acute ischemic stroke

Endovascular treatment can improve patient outcomes after acute ischemic stroke

Canadian researchers have completed an international randomized controlled trial showing that a clot retrieval procedure, known as endovascular treatment (ET), can dramatically improve patient outcomes after an acute ischemic stroke. The study, led by researchers at the University of Calgary's Hotchkiss Brain Institute (HBI), shows a dramatic improvement in outcomes and a reduction in deaths from stroke. [More]
Landmark study heralds new era in stroke treatment worldwide

Landmark study heralds new era in stroke treatment worldwide

A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe. [More]
New stent for treating cardiovascular disease successfully implanted in patients

New stent for treating cardiovascular disease successfully implanted in patients

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time. [More]
Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Neovasc Inc. today announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina, were published today in the New England Journal of Medicine. [More]
Scripps Green Hospital treats peripheral artery disease patient using new drug-coated balloon

Scripps Green Hospital treats peripheral artery disease patient using new drug-coated balloon

A doctor at Scripps Green Hospital this week became the first in California to use a new drug-coated balloon to treat peripheral artery disease in a patient since regulatory approval of the IN.PACT Admiral device in January by the Food and Drug Administration. [More]
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®. [More]
Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science is today celebrating its unique collaboration with University College London (UCL), one of the world's leading universities, to advance bio-medical research and bring real innovation to areas of high unmet medical need. [More]
EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

Magnus Life Science today announces that the European Medicines Agency's Committee for Orphan Medicinal Products has reached a positive decision on recommending orphan designation to Magnus Growth's novel therapy to treat placental insufficiency. [More]
Researchers examine ischemic complications in patients who receive flow-diverting stents

Researchers examine ischemic complications in patients who receive flow-diverting stents

The use of flow-diverting stents to treat intracranial aneurysms appears safe and highly successful. Recently, however, there have been reports of ischemic complications occurring in brain territories supplied by the parent artery in which the stent is placed and in brain regions fed by small arterial branches whose ostia are covered by the stent. [More]
Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people. [More]
Advertisement
Advertisement